서울대학교 중앙도서관
S-Space 소개
My S-Space
로그인이 필요합니다.
Login

S-Space

Browse

Author

Jump to a point in the index
Or type in a year

  • Sort by
  • In order
  • Results/Page
  • Authors/record

Showing results 421 to 480 of 527

Issue DateTitle / Author(s) / CitationFileAltmetrics
2019-01
MONARCH 3 final PFS: a randomized study of abemaciclib as initial therapy for advanced breast cancer
DOI
2019-04
Pan-PIM kinase inhibitor AZD1208 suppresses tumor growth and synergistically interacts with AKT inhibition in gastric cancer cells
DOI
2019-04
OlympiAD final overall survival and tolerability results: Olaparib versus chemotherapy treatment of physician's choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer
DOI
2019-05
Quality of life outcomes including neuropathy-associated scale from a phase II, multicenter, randomized trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy for HER2-negative metastatic breast cancer: Korean Cancer Study Group Trial (KCSG BR13-11)
view fileDOI
2019-05
Palbociclib plus letrozole as first-line therapy in postmenopausal Asian women with metastatic breast cancer: Results from the phase III, randomized PALOMA-2 study
DOI
2019-05
Prognostic effects of abnormal DNA damage response protein expression in breast cancer
DOI
2019-06
Challenges and insights of early oncology drug development in the Asia-Pacific region: introduction of phase I oncology clinical trial center and experience sharing for early clinical trials in Seoul National University Hospital, Korea
view fileDOI
2019-07
Overall survival with ribociclib plus endocrine therapy in breast cancer
DOI
2019-07
Prognostic role of body mass index is different according to menopausal status and tumor subtype in breast cancer patients
DOI
2019-07
Immune recurrence score using 7 immunoregulatory protein expressions can predict recurrence in stage I–III breast cancer patients
DOI
2019-08
Antitumor effect of CDK4/6 inhibitor, palbociclib, in acquired lapatinib resistant HER2-positive breast cancer cells
view filelink
2019-09
성인 고형암 환자의 고칼슘혈증 치료현황과 치료효과 분석

신다은; 박설희; 김성환; 서성연; 조윤희; 조윤숙; 임석아; 이주연

한국임상약학회지, Vol.29 No.3, pp.166-172

DOI
2019-09
Molecular alterations and poziotinib efficacy, a pan-HER inhibitor, in human epidermal growth factor receptor 2 (HER2)-positive breast cancers: Combined exploratory biomarker analysis from a phase II clinical trial of poziotinib for refractory HER2-positive breast cancer patients
DOI
2019-09
Pharmacokinetics of pertuzumab administered concurrently with trastuzumab in Chinese patients with HER2-positive early breast cancer
DOI
2019-10
Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial
DOI
2019-10
Ribociclib and Endocrine Therapy in Breast Cancer REPLY

Im, Seock-Ah; Lu, Yen-Shen; Tripathy, Debu

New England Journal of Medicine, Vol.381 No.16, pp.1592-1593

DOI
2019-10
The HER2 S310F Mutant Can Form an Active Heterodimer with the EGFR, Which Can Be Inhibited by Cetuximab but Not by Trastuzumab as well as Pertuzumab
DOI
2019-10
Treating HR+/HER2-breast cancer in premenopausal Asian women: Asian Breast Cancer Cooperative Group 2019 Consensus and position on ovarian suppression
DOI
2019-11
Exploratory biomarker analysis from a phase II clinical trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine for HER2-negative metastatic breast cancer patients (KCSG BR13-11)
DOI
2019-12
Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2+metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16)
DOI
2019-12
Amenorrhea and menopause in patients with breast cancer after chemotherapy
DOI
2019-12
Prognostic Impact of Pregnancy in Korean Patients with Breast Cancer
DOI
2019-12
Contrasting Epidemiology and Clinicopathology of Female Breast Cancer in Asians vs the US Population
DOI
2019-12
Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): A multicentre, open-label, randomised, phase 2 trial
DOI
2019-12
Targeted next-generation DNA sequencing identifies Notch signaling pathway mutation as a predictor of radiation response

Jeon, Seung Hyuck; Chie, Eui Kyu; Kim, Yi-Jun; Lee, Kyung-Hun; Lee, Hyun-Seob; Kim, Min Jung; Im, Seock-Ah; Kim, Jong-Il; Kim, Tae-You

International Journal of Radiation Biology, Vol.95 No.12, pp.1640-1647

DOI
2020
Clinical Implication of Next Generation Sequencing for Patients with Metastatic Breast Cancer
view filelink
2020-01
Biomarker Analyses of Response to Cyclin-Dependent Kinase 4/6 Inhibition and Endocrine Therapy in Women with Treatment-Naive Metastatic Breast Cancer
DOI
2020-02
TDP1 and TOP1 Modulation in Olaparib-Resistant Cancer Determines the Efficacy of Subsequent Chemotherapy
view fileDOI
2020-02
Overall Survival with Ribociclib plus Fulvestrant in Advanced Breast Cancer
DOI
2020-02
Trastuzumab Deruxtecan in Previously Treated HER2-Positive Breast Cancer
DOI
2020-02
Adding Ovarian Suppression to Tamoxifen for Premenopausal Breast Cancer: A Randomized Phase III Trial
DOI
2020-02
Survival outcomes of breast cancer patients with brain metastases: A multicenter retrospective study in Korea (KROG 16-12)
DOI
2020-02
PARP Inhibitors as Therapeutics: Beyond Modulation of PARylation

Min, Ahrum; Im, Seock-Ah

Cancers, Vol.12 No.2, p. 394

DOI
2020-02
Bevacizumab as adjuvant treatment of colon cancer: updated results from the S-AVANT phase III study by the GERCOR Group
DOI
2020-03
Morning chronotype is a protective factor against chemotherapy-induced hot flashes in premenopausal women with breast cancer
DOI
2020-03
Hematologic adverse events following palbociclib dose reduction in patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer: pooled analysis from randomized phase 2 and 3 studies
DOI
2020-03
The effect of perceived social support on chemotherapy-related symptoms in patients with breast cancer: A prospective observational study
DOI
2020-04
Prognostic role of androgen receptor expression in surgically resected early breast cancer patients
DOI
2020-04
Development of a Nomogram to Predict the Recurrence Score of 21-Gene Prediction Assay in Hormone Receptor–Positive Early Breast Cancer
DOI
2020-04
Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study
DOI
2020-04
Pan-Asian adapted ESMO Clinical Practice Guidelines for the management of patients with early breast cancer: a KSMO-ESMO initiative endorsed by CSCO, ISMPO, JSMO, MOS, SSO and TOS
DOI
2020-05
Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study
DOI
2020-05
Olaparib monotherapy for Asian patients with a germline BRCA mutation and HER2-negative metastatic breast cancer: OlympiAD randomized trial subgroup analysis
DOI
2020-06
Effect of timing of gonadotropin-releasing hormone agonist administration for ovarian protection in patients with breast cancer
DOI
2020-06
Abemaciclib plus trastuzumab with or without fulvestrant versus trastuzumab plus standard-of-care chemotherapy in women with hormone receptor-positive, HER2-positive advanced breast cancer (monarcHER): A randomised, open-label, phase 2 trial
DOI
2020-06
Antitumor effect of a WEE1 inhibitor and potentiation of olaparib sensitivity by DNA damage response modulation in triple-negative breast cancer
DOI
2020-07
Clinicopathological Features of Patients with the BRCA1 c.5339T > C (p.Leu1780Pro) Variant
DOI
2020-07
Prediction of pathologic complete response using image-guided biopsy after neoadjuvant chemotherapy in breast cancer patients selected based on MRI findings: a prospective feasibility trial
DOI
2020-07
Immunogenicity of influenza vaccination in patients with cancer receiving immune checkpoint inhibitors
DOI
2020-07
Homologous repair deficiency score for identifying breast cancers with defective DNA damage response
DOI
2020-09
Olaparib and durvalumab in patients with germline BRCA-mutated metastatic breast cancer (MEDIOLA): an open-label, multicentre, phase 1/2, basket study
DOI
2020-10
Trastuzumab emtansine plus atezolizumab versus trastuzumab emtansine plus placebo in previously treated, HER2-positive advanced breast cancer (KATE2): a phase 2, multicentre, randomised, double-blind trial
DOI
2020-10
Circulating Osteocalcin-Positive Cells as a Novel Diagnostic Biomarker for Bone Metastasis in Breast Cancer Patients
DOI
2020-10
Phase II Trial of Postoperative Adjuvant Gemcitabine and Cisplatin Chemotherapy Followed by Chemoradiotherapy with Gemcitabine in Patients with Resected Pancreatic Cancer
DOI
2020-10
Adjuvant Chemotherapy in Microsatellite Instability-High Gastric Cancer
DOI
2020-11
Patient-Reported Outcomes of Palbociclib Plus Exemestane with GnRH Agonist versus Capecitabine in Premenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer: A Prospective, Open-Label, Randomized Phase ll Trial (KCSG-BR 15-10)
DOI
2020-11
HLA-B27 association of autoimmune encephalitis induced by PD-L1 inhibitor

Chang, Hyeyeon; Shin, Yong-Won; Keam, Bhumsuk; Kim, Miso; Im, Seock-Ah; Lee, Soon-Tae

Annals of Clinical and Translational Neurology, Vol.7 No.11, pp.2243-2250

DOI
2020-12
Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial
DOI
2020-12
Clinical implications of HER2 mRNA expression and intrinsic subtype in refractory HER2-positive metastatic breast cancer treated with pan-HER inhibitor, poziotinib
DOI
2020-12
Combined the SMAC mimetic and BCL2 inhibitor sensitizes neoadjuvant chemotherapy by targeting necrosome complexes in tyrosine aminoacyl-tRNA synthase-positive breast cancer
DOI
15 6 7 8 9